Virtual Library
Start Your Search
D. Grapsa
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-123 - Serum and Pleural Fluid VEGF Levels in Advanced NSCLC (ID 89)
09:30 - 09:30 | Author(s): D. Grapsa
- Abstract
Background:
Although most previous studies have suggested that higher pretreatment serum vascular endothelial factor (VEGF) levels may be associated with reduced survival in patients with non-small cell lung cancer (NSCLC), the independent prognostic value of this biomarker remains largely controversial. The primary aim of this study was to evaluate the prognostic significance of pretreatment serum and pleural fluid VEGF levels in NSCLC patients presenting with malignant pleural effusion (MPE).
Methods:
Forty consecutive newly diagnosed NSCLC patients with MPE at presentation but without distant metastases were prospectively enrolled. Serum and pleural fluid VEGF levels were assayed by enzyme-linked immunoassay (ELISA). ROC curve analysis was used to determine the optimal cut-off value for serum VEGF to discriminate between patients and healthy subjects. Serum and pleural fluid VEGF levels were correlated with standard clinicopathological parameters, including gender, age, smoking history, performance status (PS), histological type of tumor and treatment response. The prognostic value of each variable for overall survival (OS) and progression-free survival (PFS) was assessed by Cox regression analysis.
Results:
The median serum VEGF levels were significantly higher in patients as compared to healthy controls (p<0.001), while the optimal cut-off of serum VEGF was 375 pg/ml, with a sensitivity and specificity of 76.9% and 98.0%, respectively. Serum VEGF more than 375 pg/ml, pleural fluid VEGF over the median value and the presence of progressive disease, were all significantly associated with reduced OS and PFS, both in univariate and multivariate analysis (Figures 1 and 2). A statistically significant correlation was also observed between serum and pleural fluid VEGF levels (p<0.001). Figure 1Figure 2
Conclusion:
Our results suggest that increased pretreatment serum and pleural fluid levels of VEGF may be independent predictors of a worse survival in advanced-stage NSCLC patients. Furthermore, pretreatment serum VEGF levels may be useful in discriminating between NSCLC patients and healthy subjects.
-
+
P3.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 226)
- Event: WCLC 2015
- Type: Poster
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.08-027 - Teratoid Wilms' Tumor of the Mediastinum in an Adult (ID 111)
09:30 - 09:30 | Author(s): D. Grapsa
- Abstract
Background:
Teratoid Wilms’ tumor is an uncommon histologic variant of nephroblastoma, which is mainly characterized by a predominance of heterologous components within the tumor mass, and typically located in the kidney. Extrarenal forms of this neoplasm are extremely rare and have been previously described almost exclusively in pediatric patients.
Methods:
We herein describe the clinical, imaging, histological and immunohistochemical features of a mediastinal teratoid Wilms’ tumor in a 63-year old female. Diagnosis was established following surgical resection and histopathological evaluation of the tumor specimen, along with documentation of complete absence of a primary renal lesion.
Results:
Microscopic examination of representative tumor sections showed the typical WT architecture consisting of blastemal, mesenchymal and epithelial components (fig.1). More than 50% of the tumor’s volume was occupied by a variety of heterologous elements. Immunohistochemistry showed positive staining of the epithelial tumor cells for pankeratin (fig.2a), while the blastematous component stained positive for CD56 (fig.2b), CD99 (fig.2c) and WT1 (fig.2d). The patient received one preoperative course of carboplatin etoposide, as well as eight and four postoperative courses of carboplatin-etoposide and cyclophosphamide-doxorubicin, respectively. Disease progression was noted 15 months following administration of the first chemotherapy cycle, and the patient died 23 months after her initial presentation. Figure 1 Figure 2
Conclusion:
Identification of the typical triphasic WT histology along with a predominant heterologous differentiation –but without evidence of unequivocal heterotopic organogenesis- as well as documentation of complete absence of a primary renal neoplasm, are all required to establish the diagnosis of this extremely rare tumor.
